Hepatocellular carcinoma
Conditions
Interventions
Group 1 (TACE+HAIC+Lenvatinib+ Camrelizumab0:NA
Group 2 (TACE+Lenvatinib+ Camrelizumab):NA
Group 3 (HAIC+Lenvatinib+ Camrelizumab):NA
Group 4 (TACE alone):NA
Sponsors
Harbin Medical University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with primary HCC with PVTT (Vp1-4) who received initial treatment with TACE or combination therapy including TACE-HAIC and a tyrosine kinase inhibitor or PD-1 inhibitor; 2. Aged between 18 and 75 years old; 3. Child-Pugh: A or B; 4. ECOG =1;
Exclusion criteria
Exclusion criteria: 1. Serious heart, lung or kidney disease; 2. A previous diagnosis of a different primary cancer; 3. Incomplete medical records; 4. Patients who cannot be followed up;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Progression-free survival;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactLiu Ruibao
Harbin Medical University Cancer Hospital
Outcome results
None listed